No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (12)
Sort:
#001 — 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▴
TABLET;ORAL | Approved: May 25, 2001
No patent or exclusivity listings for this strength.
#002 — 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#003 — 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#004 — 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#005 — 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#006 — 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#007 — 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#008 — 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#009 — 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#010 — 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#011 — 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
RLDAB1,AB3
0 patents0 exclusivities▾
TABLET;ORAL | Approved: May 25, 2001
#012 — 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**